The C-reactive protein to albumin ratio as a predictor of severe side effects of adjuvant chemotherapy in stage III colorectal cancer patients

8Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

© 2016 Tominaga et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Background/Aims: Adjuvant chemotherapy (AC) has been reported to improve the prognosis for patients with Stage III colorectal cancer (CRC). However, some patients experience severe side effects and must stop AC. The C-reactive protein (CRP) to albumin ratio (CAR) is a novel inflammation- based score that could reflect the patient's general condition. The aim of this study was to evaluate the predictive value of the CAR for side effects of AC in CRC. Methods: A total of 136 CRC patients who received AC were retrospectively analyzed. The patients were subdivided into two groups by the CAR level (CAR ≥0.1, n = 30; CD < 0.1, n = 106). Results: The presence of lymphatic invasion, severe side effects, and discontinuation of AC were associated with high CAR levels (p = 0.02, < 0.01, and 0.02; respectively). High levels of the Glasgow Prognostic Score (GPS) and the neutrophil to lymphocyte ratio (NLR) appeared to be associated with the CAR (p = 0.04, p < 0.01; respectively). Multivariate analysis identified CAR≥0.1 (HR: 7.06, 95% CI: 2.51±19.88, p < 0.01) as a significant determinant of severe side effects of AC. CAR had the highest area under the curve (0.79) among several inflammation- based scores. Conclusion: The present study showed that the CAR is a novel and promising inflammation-based score for ≥ grade 3 side effects of AC in node-positive CRC.

Cite

CITATION STYLE

APA

Tominaga, T., Nonaka, T., Sumida, Y., Hidaka, S., Sawai, T., & Nagayasu, T. (2016). The C-reactive protein to albumin ratio as a predictor of severe side effects of adjuvant chemotherapy in stage III colorectal cancer patients. PLoS ONE, 11(12). https://doi.org/10.1371/journal.pone.0167967

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free